1. Van Ermengem E. A new anaerobic bacillus and
its relation to botulism. Rev Infect Dis 1979;1:701–719.
2. Snipe PT, Sommer H. Studied on botulinus toxin. 3. Acid
precipitation of botulinus toxin. J Infect Dis 1928;43:152–160.
3. Shantz EJ. Historical perspective. In: Jankovic J, Hallett
M, eds. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker;
1994:_ 23–36____.
4. Scott AB, Rosenbaum AL, Collins CC. Pharmacologic weakening
of extra-ocular muscles.
Invest Ophthalmol 1973;12:924–927.
[PubMed: 4203467]
5. Scott AB. Botulinum toxin injection into extra-ocular muscles
as an alternative to strabismus surgery.
Ophthalmology 1980;87:1044–1049.
[PubMed: 7243198]
6. Tsui JKC. Botulinum toxin as a therapeutic agent.
Pharmacol
Ther 1996;72:13–24.
[PubMed: 8981568]
7. Jankovic J, Hallett M, eds. Therapy with Botulinum Toxin.
New York, NY: Marcel Dekker; 1994.
8. DasGupta BR. Structures of botulinum neurotoxin, its functional
domains, and perspectives on the crystalline type A toxin. In: Jankovic
J, Hallett M, eds. Therapy with Botulinum Toxin. New York, NY: Marcel
Dekker; 1994:15–39.
9. Hesse S, Lucke D, Malezic M, et al. Botulinum toxin treatment
for lower limb extensor spasticity in chronic hemiparetic patients.
J Neurol Neurosurg Psychol 1994;57:1321–1324.
[PubMed: 7964805]
10. Sellin LC, Thesless S, Dasgupta BR. Different effects of
types A and B botulinum toxin on transmitter release at the rat
neuromuscular junction.
Acta Physiol Scand 1983;119(2):127–133.
[PubMed: 6140815]
11. Sellin LC, Kauffman JA, Dasgupta BR. Comparison of the
effects of botulinum neurotoxin types A and E at the rat neuromuscular
junction.
Med Biol 1983;61(2):120–125.
[PubMed: 6308364]
12. Kauffman JA, Way JF, Siegel LS, Sellin LC. Comparison of
the action of types A and F botulinum toxin at the rat neuromuscular
junction.
Toxicol Appl Pharmacol 1985;79(2):211–217.
[PubMed: 2988154]
13. Schantz EJ, Johnson EA. Preparation and characterization
of botulinum toxin type A for human treatment. In: Jankovic J, Hallett
M, eds. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker;
1994:41–49.
14. Sugiyama H. Clostridium botulinum neurotoxin.
Microbiol
Rev 1980;44:419–448.
[PubMed: 6252433]
15. Moyor E, Settler PE. Botulinum toxin type B: experimental
and clinical experience In: Jankovic J, Hallett M, eds. Therapy
with Botulinum Toxin. New York, NY: Marcel Dekker; 1994:71–86.
16. Borodic GE, Pearce LB, Smith KL, et al. Botulinum B toxin
as an alternative to botulinum A toxin: a histology study.
Ophthal
Plast Reconstr Surg 1993;9:182–190.
[PubMed: 8217959]
17. Greene P, Fahn S. Use of botulinum toxin type F injections
to treat torticollis in patients with immunity to botulinum toxin
type A.
Mov Disord 1993;8:479–483.
[PubMed: 8232357]
18. Ludlow CL, Hallett M, Rhew K, et al. Therapeutic use of
type F botulinum toxin.
N Engl J Med 1992;326:349–350.
[PubMed: 1728750]
19. DasGupta BR. Structure and biological activity of botulinum
neurotoxin. J Physiol (Paris) 1990:84:220–228.
20. Montccucco C. How do tetanus and botulinum toxins bind
to neuronal membranes? Trends Biochem Sci 1986:11:314–317.
21. Evans DM, Williams RS, Shone CC, Hambleton P, Melling J,
Dolly JO. Botulinum neurotoxin type B: its purification, radioiodination
and interaction with rat-brain synaptosomal membranes. Eur J Biochem
1986:154:409–416.
22. Black JD, Dolly JO. Interaction of 125I-labeled botulinum
neurotoxins with nerve terminals. I. Ultrastructural autoradiographic
localization and quantitation of distinct membrane acceptors for
types A and B on motor nerves. J Cell Biol 1986:103:521–534.
23. Burgen AS, Dickens VF, Zatman LJ. The action of botulinum
toxin on the neuromuscular junction.
J Physiol (London) 1949;109:10–24.
[PubMed: 15394302]
24. Simpson LL. The study of clostridial and related toxins.
The search for unique mechanisms and common denominators.
J Physiol
(Paris) 1990;84:143–151.
[PubMed: 2290129]
25. Poulain B, Tauc L, Maisery EA, et al. Neurotransmitter
release is blocked intracellularly by botulinum neurotoxin, and
this requires uptake of both toxin polypeptides by a process mediated by
the larger chain.
Proc Natl Acad Sci USA 1988;85:4090–4094.
[PubMed: 2897693]
26. Finkelstein A. Channels formed in phospholipid bilayer
membranes by diphtheria, tetanus, botulinum and anthrax toxin.
J
Physiol (Paris) 1990;84:188–190.
[PubMed: 1705290]
27. Schiavo G, Boquet P, DasGupta BR, Montecucco C. Membrane
interactions of tetanus and botulinum neurotoxins: a photolabelling
study with photoactivatable phospholipid.
J Physiol (Paris) 1990;84:180–187.
[PubMed: 2290132]
28. Duchen LW, Strich SJ. The effects of botulinum toxin on
the pattern of innervation of skeletal muscle in the mouse.
Q J
Exp Physiol 1968;53:84–89.
[PubMed: 4297234]
29. Elston JS. Botulinum toxin treatment of blepharospasm.
In: Fahn S, Marsden CD, eds. Dystonia 2. New York, NY: Raven Press;
1988:579–581.
30. Borodic GE, Ferrante R. Histologic effects of repeated
botulinum toxin over many years in human orbicularis oculi muscle.
J Clin Neuroophthalmol 1992;12:121–127.
[PubMed: 1385821]
31. Harris CP, Alderson K, Nebeker J, et al. Histology of human
orbicularis muscle Treated with botulinum toxin.
Arch Ophthalmol
1991;109:393–395.
[PubMed: 2003801]
32. Borodic GE, Ferrante RJ, Pearce LB, Alderson K. Pharmacology
and histology of the therapeutic application of botulinum toxin.
In: Jankovic J, Hallett M, eds. Therapy with Botulinum Toxin. New
York, NY: Marcel Dekker; 1994:119–157.
33. Purkiss J, Welch M, Doward D, Foster K. Capsaicin-stimulated
release of substance P from cultured dorsal root ganglion neurons:
involvement of two distinct mechanisms.
Biochem Pharmacol 2000;59:1403–1406.
[PubMed: 10751549]
34. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic
rat dorsal root ganglia neurons to
Clostridium botulinum neurotoxins.
Toxicon 2000;38:245–258.
[PubMed: 10665805]
35. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects
of botulinum toxin type A on neuronally evoked response of albino
and pigmented rabbit iris sphincter and dilator muscles.
Jpn J Ophthalmol
2000;44:106–109.
[PubMed: 10715374]
36. Cui ML, Khanijou S, Rubino J, Aoki KR. Botulinum toxin
A inhibits the inflammatory pain in the rat formalin model. Poster
246.2. Presented at the Society for Neuroscience Annual Meeting; New
Orleans, LA; 2000.
37. Dekker, Inc. 1994. This is a comprehensive textbook devoted
to the therapeutic uses of BTX-A and is an excellent starting place
for background information. There is also a multiauthor textbook
to be published by Lippincott Williams and Williams in spring 2001
by WeMOVE (Worldwide Education and Awareness for Movement Disorders),
Brin MF, Jankovic J, and Hallett M, eds.
38. Racz GB. Botulinum toxin as a new approach for refractory
pain syndromes. Pain Digest 1998;8:353–356.
39. Porta M, Perretti A, Gamba M, Luccarelli G, Fornari M.
The rationale and results of treating muscle spasm and myofascial
syndromes with botulinum toxin type A. Pain Digest 1998;8:346–352.
40. Hatheway CL, Dang C. Immunogenicity of neurotoxins of Clostridium
botulinum. In: Jankovic J, Hallett M, eds. Therapy with Botulinum
Toxin. New York, NY: Marcel Dekker; 1994:93–107.
41. Brin MF, Fahn S, Moskowitz C, et al. Localized injections
of botulinum toxin for the treatment of focal dystonia and hemifacial
spasm.
Mov Disord 1987;2:237–254.
[PubMed: 3504553]
42. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type
B: a double-blind placebo-controlled, safety and efficacy study
in cervical dystonia.
Neurology 1997;49:701–707.
[PubMed: 9305326]
43. Abrams BM. Tutorial 36: myofascial pain syndrome and fibromyalgia.
Pain Digest 1998;8:264–272.
44. Lang AM. Botulinum toxin for myofascial pain. In: Advancements
in the Treatment of Neuromuscular Pain. Ch 5. Baltimore, MD: Johns
Hopkins University Office of Continuing Medical Education Syllabus;
1999:23–28.
45. Atassi MZ, Oshima M. Structure, activity and immune (T
and B cell) recognition of botulinum neurotoxins.
Crit Rev Immunol
1999;19:219–260.
[PubMed: 10422600]
46. Chen R, Karp BI, Hallett M. Botulinum toxin type F for
treatment of dystonia: long-term experience.
Neurology 1998;51:1494–1496.
[PubMed: 9818895]
47. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment
of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias
and hemifacial spasm.
J Neurol Neurosurg Psychiatry 1990;53:633–639.
[PubMed: 2213039]
48. Tsui JKC, Eisen A, Stoessl HA, et al. Double-blind study
of botulinum toxin in spasmodic torticollis.
Lancet 1986;2:245–247.
[PubMed: 2874278]
49. Polo KB, Jabbari B. Botulinum toxin A improved the rigidity
of progressive supranuclear palsy.
Ann Neurol 1994;35:237–239.
[PubMed: 8109906]
50. Porta M. A comparative trial of botulinum toxin type A
and
methylprednisolone for the treatment of myofascial pain syndrome
and pain from chronic muscle spasm.
51. Relja M. Botulinum toxin type A in the treatment of tension-type
headache. Presented at the 9th World Congress on Pain; Vienna, Austria;
August 22–27, 1999, and at the International Conference
1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins;
Orlando, FL; November 16–18, 1999.
52. Schulte-Mattler WJ, Wieser T, Zierz S. Treatment of tension-type
headache with botulinum toxin: a pilot study. Eur J Med Res 1999;4:183–186.
These data were also presented at the International Conference 1999:
Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins; Orlando,
FL; November 16–18, 1999.
53. Smuts JA, Baker MK, et al. Botulinum toxin type A as prophylactic
treatment in chronic tension-type headache. Presented at the International
Conference 1999: Basic and Therapeutic Aspects of Botulinum and
Tetanus Toxins; Orlando, FL; November 16–18, 1999. See
also: Smuts JA, Baker MK, Smuts HM, Theta Stassen JM, Rossouw E,
Barnard PWA. Prophylactic treatment of chronic tension-type headache
using botulinum toxin type A. Eur J Neurol 1999;6(suppl 4):S99–S102.
54. Wheeler AH. Botulinum toxin A, adjunctive therapy for refractory
headaches associated with pericranial muscle tension.
Headache 1998;38:468–471.
[PubMed: 9664753]
55. Barwood S, Baillieu C, Boyd R, et al. Analgesic effects
of botulinum toxin A: a randomised, placebo trial.
Dev Med Child
Neurol 2000;42:116–121.
[PubMed: 10698329]
56. Fish DR, Sawyers D, Allen PJ, Blackie JD, Lees AJ, Marsden
CD. The effect of sleep on the dyskinetic movements of Parkinson’s
disease, Gilles de la Tourette syndrome, Huntington’s disease,
and torsion dystonia.
Arch Neurol 1991;48:210–214.
[PubMed: 1825167]
57. Poewe W, Wissel J. Experience with botulinum toxin in cervical
dystonia. In: Jankovic J, Hallett M, eds. Therapy with Botulinum
Toxin. New York, NY: Marcel Dekker; 1994:267–278.
58. Sheehy MP, Marsden CD. Writer’s cramp—focal
dystonia.
Brain 1982;105:461–480.
[PubMed: 7104663]
59. Hunter D. The Diseases of Occupations. 6th ed. London,
UK: Hodder & Stoughton; 1978.
60. Gowers WR. A Manual of Diseases of the Nervous System.
Philadelphia, PA: P. Blakiston; 1888.
61. Albanese A, Bentivoglio AR, Cassetta E, Viggiano A, Maria
G, Gui D. Review article: the use of botulinum toxin in the alimentary
tract.
Aliment Pharmacol Ther 1995;9(6):599–604.
[PubMed: 8824646]
62. Cohen LG, Hallett M, Celler BD, Hochberg F. Treatment of
focal dystonia of the hand with botulinum toxin injections. J Neurol
Neurosurg Psychaiatry 1989:52:355–363.
63. Cole RA, Cohen LG, Hallett M. Treatment of musician’s
cramp with botulinum toxin. Med Probl Performing Artists 1991;6:137–143.
64. Poungvarin N. Writer’s cramp: the experience with
botulinum toxin injections in 25 patients.
J Med Assoc Thai 1991;74:239–247.
[PubMed: 1783871]
65. Rivest J, Lees AJ, Marsden CD. Writer’s cramp:
treatment with botulinum toxin injections. Mov Discord 1991:6:55–59.
66. Jankovic J, Schwartz KS. Use of botulinum toxin in the
treatment of hand dystonia. J Hand Surg 1993;18A:883–887.
67. Karp BI, Cole RA, Cohen LG, Grill S, Lou J-S, Hallett M.
Long-term botulinum toxin treatment of focal hand dystonia.
Neurology
1994;44:70–76.
[PubMed: 8290095]
68. Tsui JKC, Bhatt M, Calne S, Clane DB. Botulinum toxin in
the treatment of writer’s cramp: a double-blind study.
Neurology 1993;43:183–185.
[PubMed: 8423882]
69. Cole R, Hallett M, Cohen LG. Double-blind trial of botulinum
toxin for treatment of focal hand dystonia.
Move Discord. 1995;10:466–471.
[PubMed: 7565828]
70. Young RR. Treatment of spastic paresis. N Engl J Med 1989:320:1553–1555.
71. Burke D. Critical examination of the case for or against
fusimotor involvement in disorder of muscle tone. In: Desmedt JE,
ed. Motor Control Mechanisms in Health and Disease. New York, NY:
Raven Press; 1983:133–150.
72. Dimitrijevic MR. Spasticity and rigidity. In: Jankovic
J, Tolosa E, eds. Parkinson’s Disease and Movement Disorders.
2nd ed. Baltimore, MD: Williams and Wilkins; 1993:443–453.
73. Simpson DM, Alexander DN, O’Brien CF, et al. Botulinum
toxin type A in the treatment of upper extremity spasticity: a randomized,
double-blind, placebo-controlled trial.
Neurology 1996;46(5):1306–1310.
[PubMed: 8628472]
74. Gordon J. Spinal mechanisms of motor coordination. In:
Kandel ER, Schwartz JH, Jessell TM, eds. Principles of Neural Science.
3rd ed. Norwalk, CT: Appleton & Lange; 1991:581–595.
75. Delwaide PJ, Yoiung (Young) RR, Eds. Clinical Neurophysiology
in Spasticity. Amsterdam, The Netherlands: Elsevier; 1985.
76. Young RR. Physiologic and pharmacologic approaches to spasticity.
Neurol Clin 1987;5:529–539.
[PubMed: 3323874]
77. Katz RT. Management of spasticity. Am J Phys Med Rehabil
1988:67:108–116.
78. Gans BM, Glenn MB. Introduction. In: Glenn MB, Whyte J,
eds. The Practical Management of Spasticity in Children and Adults.
Philadelphia, PA: Lea & Febiger; 1990:1–7.
79. Mayer NH. Functional management of spasticity after head
injury. J Neurol Rehab 1991;5:S1–S4.
80. Lehmkuhl LD, Thoi LL, Baize C, Kelley CJ, Krawcryk L, Bontke
CF. Multimodality treatment of joint contractures in patients with
severe brain injury: cost, effectiveness, and integration of therapies
in the application of seria Vinhibitive casta. serial/inhibitive
casts J Head Trauma Rehabil 1990;5:23–42.
81. Carthidge NE, Hudgson P, Weightman D. A comparison of
baclofen
and
diazepam in the treatment of spasticity.
J Neurol Sci 1974:23:17–24.
82. Whyte J, Robinson KM. Pharmacologic management. In: Glenn
MB, Whyte J, eds. The Practical Management of Spasticity in Children
and Adults. Philadelphia, PA: Lea & Febiger; 1990:201–226.
83. Chan CH.
Dantrolene sodium and hepatic injury.
Neurology
1999;40:1427–1432.
84. Reeves KD, Baker A. Mixed somatic peripheral nerve block
for painful or intractable spasticity: a review of 30 years of use.
AJPM Am J Phys Med Rehabil 1992;2:205–210.
85. Glenn MB. Nerve blocks. In: Glenn MB, Whyte J, eds. The
Practical Management of Spasticity in Children and Adults. Philadelphia,
PA: Lea & Febiger; 1990:227–258.
86. Kasdon KL, Abromovitz JN. Neurosurgical approaches. In:
Glenn MB, Whyte J, eds. The Practical Management of Spasticity in
Children and Adults. Philadelphia, PA: Lea & Febiger; 1990:259–267.
87. Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J.
Continuous intrathecal
baclofen infusion for spasticity of cerebral
origin.
JAMA 1993;270:2476–2477.
88. Bowers DN, Averill A. Intrathecal
baclofen for Intractable
spasticity due to severe traumatic brain injury (abstract).
Arch
Phys Med Rehabil 1991;72:816.
89. Meythaler JM. Use of intrathecal
baclofen in brain injury
patients (abstract).
Arch Phys Med Rehabil 1994;75:1036.
90. Shaari CM, Sanders I. Assessment of the biological activity
of botulinum toxin. In: Jankovic J, Hallett M, eds. Therapy with
Botulinum Toxin. New York, NY: Marcel Dekker; 1994:159–170.
91. Han SC, Harrison P. Myofascial pain syndrome and trigger-point
management. Reg Anesth 1995;65:167–70.
92. Flax HJ. Myofascial pain syndromes—the great mimicker.
Bol Asoc Med P R 1995;65:167–170.
93. Schneider MJ. Tender points/fibromyalgia vs. trigger
points/myofascial pain syndrome: a need for clarity in
terminology and differential diagnosis. J Manipulative Physiol Ther 1995;65:398–406.
94. Tschopp KP, Gysin C. Local injection therapy in 107 patients
with myofascial pain syndrome of the head and neck.
ORL J Otorhinolaryngol
Relat Spec 1996;58:306–310.
[PubMed: 8958538]
95. Wreje U, Brorsson B. A multicenter randomized controlled
trial of injections of sterile water and saline for chronic myofascial
pain syndromes. Pain 1995;65:441–444.
96. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the
treatment of myofascial pain syndrome.
Pain 1994;59:65–69.
[PubMed: 7854804]
97. Holz RW, Fisher SK. Synaptic transmission and cellular
signaling; an overview. In: Siegal GJ, Siegel, GJ et al., eds. Basic
Neurochemistry: Molecular, Cellular and Medical Aspects. 6th ed.
Ch 10. Lippincott-Raven OK Publishers; 1999:191–212.
98. Note that because
albumin is a derivative from human blood,
despite effective donor screening and manufacturing processes an
extremely remote risk for transmission of viral diseases and Creutzfeldt-Jakob
disease exists. To date, no case of such transmission has ever been
identified for
albumin.